Intercept Pharma (ICPT) Receives a Buy from RBC Capital

By Austin Angelo

In a report issued on April 6, Brian Abrahams from RBC Capital maintained a Buy rating on Intercept Pharma (ICPTResearch Report), with a price target of $117.00. The company’s shares closed last Tuesday at $62.91.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 7.8% and a 50.9% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.

Currently, the analyst consensus on Intercept Pharma is a Strong Buy with an average price target of $149.08, representing a 127.0% upside. In a report issued on March 26, Wedbush also reiterated a Buy rating on the stock with a $257.00 price target.

See today’s analyst top recommended stocks >>

Based on Intercept Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $71.5 million and GAAP net loss of $98.16 million. In comparison, last year the company earned revenue of $53.28 million and had a GAAP net loss of $88.01 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.